7 unchanged sentences
4.1 Reference is made to Exhibits 3.1 through 3.3.
−Removed: 10.1 * Platform Technology Transfer, Collaboration and License Agreement by and between the Company and GlaxoSmithKline Intellectual Property Limited, effective as of July 10, 2014.
+Added: 10.1 + Transition and Separation Agreement by and between the C o mpany and John Nicols , dated as of July 18 , 2022.
+Added: 10.2 + Employment Agreement by and between the Company and Stephen Dilly dated as of August 9, 2022 .
+Added: 10.3 + Offer Letter by and between the Company and Kevin Norrett dated as of September 12 , 2022 .
+Added: 10.4 + Change in Control Severance Agreement by and between the Company and Kevin Norrett dated September 12, 2022.
+Added: 10.5 * Enzyme Supply Agreement by and between the Company and Pfizer Ireland Pharmaceuticals, dated as of July 14, 2022.
31.1 Certification of Principal Executive Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.
1 unchanged sentence
32.1 Certification of Principal Executive Officer and Principal Financial Officer Required Under Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C.
−Removed: 101 The following materials from the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, formatted in Inline Extensible Business Reporting Language ("iXBRL") includes:
−Removed: (i) Unaudited Condensed Consolidated Balance Sheets at June 30, 2022 and December 31, 2021 (ii) Unaudited Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2022 and 2021, (iii) Unaudited Condensed Consolidated Statements of Stockholders' Equity for the Three and Six Months Ended June 30, 2022 and 2021, (iv) Unaudited Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2022 and 2021 and (v) Notes to Unaudited Condensed Consolidated Financial Statements.
+Added: 101 The following materials from the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, formatted in Inline Extensible Business Reporting Language ("iXBRL") includes:
+Added: (i) Unaudited Condensed Consolidated Balance Sheets at September 30, 2022 and December 31, 2021 (ii) Unaudited Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2022 and 2021, (iii) Unaudited Condensed Consolidated Statements of Stockholders' Equity for the Three and Nine Months Ended September 30, 2022 and 2021, (iv) Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2022 and 2021 and (v) Notes to Unaudited Condensed Consolidated Financial Statements.
101.SCH Inline XBRL Taxonomy Extension Schema Document
3 unchanged sentences
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document
−Removed: 104 The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, formatted in Inline XBRL and contained in Exhibit 101.
+Added: 104 The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, formatted in Inline XBRL and contained in Exhibit 101.
+Added: + Indicates a management contract or compensatory plan or arrangement.
* Portions of the exhibit, marked by brackets, have been omitted because the omitted information is (i) not material and (ii) would be competitively harmful if publicly disclosed.
1 unchanged sentence
Codexis, Inc.
−Removed: August 5, 2022 By:
+Added: November 4, 2022 By:
+Added: /s/ Stephen Dilly
+Added: Stephen Dilly
President and Chief Executive Officer
(principal executive officer)
−Removed: August 5, 2022 By:
+Added: November 4, 2022 By:
/s/ Ross Taylor
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.